Results 301 to 310 of about 4,993,363 (331)
Some of the next articles are maybe not open access.
Biopharmaceutics & drug disposition, 2019
Mycophenolic acid (MPA) is used widely to prevent graft rejection in kidney‐transplant patients. Therapeutic drug monitoring (TDM) in plasma requires an invasive procedure that is inconvenient, especially in pediatric patients.
Mo’tasem M. Alsmadi +8 more
semanticscholar +1 more source
Mycophenolic acid (MPA) is used widely to prevent graft rejection in kidney‐transplant patients. Therapeutic drug monitoring (TDM) in plasma requires an invasive procedure that is inconvenient, especially in pediatric patients.
Mo’tasem M. Alsmadi +8 more
semanticscholar +1 more source
Journal of Pharmaceutical and Biomedical Analysis, 2004
Mycophenolic acid (MPA), the active metabolite of the prodrug mycophenolate mofetil is an immunosuppressive agent which inhibits inosine monophosphate dehydrogenase. MPA is metabolised to phenolic glucuronide (MPAG) that may be hydrolysed in vivo to form free MPA. Drug monitoring is required in patients with multi-organ failure.
Karim Chelbi +5 more
openaire +3 more sources
Mycophenolic acid (MPA), the active metabolite of the prodrug mycophenolate mofetil is an immunosuppressive agent which inhibits inosine monophosphate dehydrogenase. MPA is metabolised to phenolic glucuronide (MPAG) that may be hydrolysed in vivo to form free MPA. Drug monitoring is required in patients with multi-organ failure.
Karim Chelbi +5 more
openaire +3 more sources
Clinical Transplantation, 2019
The practice of induction therapy with either rabbit anti‐thymocyte globulin (r‐ATG) or interleukin‐2 receptor antagonists (IL‐2RA) is common among heart transplant recipients.
A. Amin +8 more
semanticscholar +1 more source
The practice of induction therapy with either rabbit anti‐thymocyte globulin (r‐ATG) or interleukin‐2 receptor antagonists (IL‐2RA) is common among heart transplant recipients.
A. Amin +8 more
semanticscholar +1 more source
Total synthesis of mycophenolic acid
Journal of the American Chemical Society, 1986AbstractThe antitumor antibiotic title compound (IX) is obtained with an overall yield of 17‐19%.
Joseph J. Perez +2 more
openaire +3 more sources
ChemInform Abstract: A Convergent Synthesis of Mycophenolic Acid (V).
ChemInform, 1997AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Geraint Jones, Annie Hamon, Patrick Ple
openaire +3 more sources
Biosynthesis of Mycophenolic Acid
Canadian Journal of Chemistry, 1973Comparative incorporation experiments with (1′-14C)-orsellinic acid (2) and (1′-14C)-4,6-dihydroxy-2,3-dimethylbenzoic acid (3) suggest that only the latter compound is a specific precursor of mycophenolic acid; the implication of this result in terms of the early stages of the biosynthetic sequence is noted.
C. T. Bedford +4 more
openaire +2 more sources
Crystal structure of mycophenolic acid
Journal of the Chemical Society, Perkin Transactions 2, 1972Crystals of the title compound, are triclinic, a= 9·555(2), b= 11·639(3), c= 7·341(3)A, α= 90·75(10), β= 90·77(5), γ= 102·70(2)°, Z= 2, space group P. The structure was determined from diffractometer data by direct methods, and was refined by full-matrix least-squares techniques to R 0·076 for 1548 observed reflexions.
J. Trotter +2 more
openaire +2 more sources
Halogenated analogues of mycophenolic acid
Journal of the Chemical Society, Chemical Communications, 1973Halogenated analogues of mycophenolic acid (I) were produced by cultures of Penicillium brevicompactum fed respectively with 4-bromo-5,7-dihydroxy-phthalide (V) and 4-chloro-5,7-dihydroxyphthalide (VI).
Renato Craveri +4 more
openaire +2 more sources